Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

New Alzheimer's Treatment Could Be on the Horizon


Related Encyclopedia
 border=
Acoustic Neurinoma
Alzheimer's Disease
Bell's Palsy
Brain and Spinal Cord Magnetic Resonance Imaging
More...

Related Healthscout Videos
 border=
The Cure Within
Killing Ourselves
Killing Ourselves
Roadmap for the Brain
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Erectile Dysfunction
What is a Heart Attack?
More...

Related Drug Information
 border=
Actonel
Adderal XR
Concerta
Coumadin
More...

Related News Articles
 border=
Wrist Fractures May Open Door to Disability in Older Women
Cumulative Radiation Doses Seen in Cardiac Imaging
FDA Advisory Panel Decision on Avandia Looms
FDA Reviewer Questions Results of Key Avandia Trial
More...


Page:  << Prev | 1 | 2 | 3 | Next >>

IVIg, which contains antibodies derived from purified human plasma, is used to treat certain immune deficiencies, autoimmune diseases and cancers.

Though researchers aren't sure of the precise mechanism, it's possible that older people lack sufficient antibodies to beta-amyloid proteins, causing the plaque to accumulate. Fillet said that IVIg might help by giving the immune system a boost and slowing down, or preventing, the buildup of the toxic plaque.

Several drug companies are also at work developing monoclonal antibodies, or artificially produced drugs, to prevent the beta-amyloid buildup.

Text Continues Below



Despite the study's promising results, the researchers said, they're not suggesting that IVIg be given as a treatment for Alzheimer's yet. A phase 3 clinical trial testing IVIg as an Alzheimer's treatment is under way, also sponsored by Baxter.

Participants in the trial are getting infusions of IVIg or a placebo every two weeks for 70 weeks, according to the U.S. National Institute of Health's online registry of clinical trials, www.clinicaltrials.gov.

The trial, which will include an estimated 360 participants, is expected to be completed in July 2011.

If the clinical trial shows that IVIg is beneficial, it could be a potent new weapon against Alzheimer's, treating the underlying cause of the disease rather than just the symptoms, Fillit said.

"I don't think we would recommend doctors do it right now, but if the clinical study works, then there's potential that doctors could start using it as soon as the results are known," he said.

Dr. Victor Henderson, a professor of epidemiology and neurology at Stanford University in California, said he agrees with the need for a clinical trial to effectively assess the value of IVIg.

Among people whose records were examined as part of the study reported in Neurology, he noted, those who had received IVIg had other serious illnesses, which might have meant doctors were less likely to burden them further with a diagnosis of Alzheimer's, Henderson said.

Page:  << Prev | 1 | 2 | 3 | Next >>

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 7/20/2009

Related Links
 border=
From Healthscout's partner site on alzheimer's disease, OurAlzheimers.com
I need to know about Alzheimer's symptoms.
What are the stages of Alzheimer's Disease?
Learn about Alzheimer's medications.





SOURCES: Howard Fillit, M.D., clinical professor, geriatrics, neuroscience and medicine, Mount Sinai School of Medicine, New York City; Victor Henderson, M.D., professor, epidemiology and neurology, School of Medicine, Stanford University, Stanford, Calif.; July 21, 2009, Neurology


About The HealthScout Network Contact Us
Copyright © 2001-2010. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy